Holen Sie sich die Stockscreener-App
20.10
1.52%
-0.3003
Schlusskurs vom Vortag:
$20.40
Offen:
$20.4
24-Stunden-Volumen:
314.73K
Relative Volume:
0.22
Marktkapitalisierung:
$2.46B
Einnahmen:
$460.48M
Nettoeinkommen (Verlust:
$142.80M
KGV:
17.03
EPS:
1.18
Netto-Cashflow:
$221.79M
1W Leistung:
-3.51%
1M Leistung:
+0.60%
6M Leistung:
-11.89%
1J Leistung:
-2.67%
1-Tages-Spanne:
$19.90
$20.46
1-Wochen-Bereich:
$19.90
$21.17
52-Wochen-Spanne:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Vergleichen Sie CPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
20.09 | 2.50B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.48 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.20 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.95 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.88 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
321.17 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Catalyst Pharmaceuticals Shares Climb as New Drug Developments Spark Fresh Valuation Debate - Yahoo Finance
Can Catalyst Pharmaceuticals Inc. (CN2) stock surprise with quarterly resultsBuy Signal & Weekly Breakout Opportunity Watchlist - newser.com
What institutional flow reveals about Catalyst Pharmaceuticals Inc.July 2025 Closing Moves & Technical Analysis for Trade Confirmation - newser.com
Catalyst Pharmaceuticals (CPRX): Assessing Valuation on Clinical Progress and Expanding Rare Disease Pipeline - Sahm
Assessing Catalyst Pharmaceuticals’ Value After Recent Positive FDA Ruling in 2025 - Sahm
Catalyst Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Should Catalyst Pharmaceuticals’ (CPRX) Share Buyback and New Data Prompt a Fresh Look at Its Strategy? - Sahm
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - sharewise.com
Using Ichimoku Cloud for Catalyst Pharmaceuticals Inc. technicalsWatch List & Consistent Growth Equity Picks - newser.com
Published on: 2025-10-10 04:19:27 - newser.com
Will earnings trigger a reversal in Catalyst Pharmaceuticals Inc.Portfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
Catalyst Pharmaceuticals (NASDAQ:CPRX) Earns "Hold (C+)" Rating from Weiss Ratings - MarketBeat
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences - GlobeNewswire
Catalyst Pharmaceuticals to Present Research on Duchenne Muscular Dystrophy and Lambert Eaton Myasthenic Syndrome at Upcoming Scientific Conferences - Quiver Quantitative
3 Presentations: Catalyst Pharmaceuticals to present DMD & LEMS data at Oct 2025 conferences - Stock Titan
Real time breakdown of Catalyst Pharmaceuticals Inc. stock performance2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
Published on: 2025-10-09 06:27:04 - newser.com
Catalyst Pharmaceuticals Delivers Growth But Faces Narrow Pipeline Risk - Finimize
Published on: 2025-10-09 00:54:28 - newser.com
Lambert Eaton Myasthenic Syndrome Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Jacobus Pharmaceutical, Catalyst Pharmaceuticals - Barchart.com
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
What do Analysts Think About Catalyst Pharmaceuticals (CPRX)? - MSN
14 Biotech Stocks with High Potential - Insider Monkey
Will Catalyst Pharmaceuticals Inc. rebound enough to break evenTrade Risk Assessment & Daily Technical Forecast Reports - newser.com
Published on: 2025-10-06 05:08:49 - newser.com
Detecting price anomalies in Catalyst Pharmaceuticals Inc. with AIEarnings Summary Report & Long-Term Capital Growth Ideas - newser.com
A Closer Look at Catalyst Pharmaceuticals (CPRX) Valuation as Shares Remain Steady This Week - Sahm
Order flow analysis tools used on Catalyst Pharmaceuticals Inc.Weekly Trade Review & Capital Efficiency Focused Strategies - newser.com
Wealth Enhancement Advisory Services LLC Lowers Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX - Defense World
Wall Street Zen Downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Hold - MarketBeat
Why Catalyst Pharmaceuticals Inc. (CN2) stock could break out in 2025July 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - newser.com
Catalyst Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
What macro factors could drive Catalyst Pharmaceuticals Inc. (CN2) stock higherPortfolio Update Report & Weekly High Conviction Trade Ideas - newser.com
Published on: 2025-10-03 06:09:02 - newser.com
Using flow based indicators on Catalyst Pharmaceuticals Inc.2025 Big Picture & Daily Stock Trend Watchlist - newser.com
Historical volatility pattern of Catalyst Pharmaceuticals Inc. visualizedJuly 2025 Breakouts & Reliable Price Breakout Alerts - newser.com
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy - The Manila Times
Share Repurchase Program Initiated by Catalyst Pharmaceuticals (NASDAQ:CPRX) Board of Directors - Defense World
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program - GlobeNewswire
Catalyst Pharma Announces $200M Share Repurchase Program - TipRanks
Catalyst Pharmaceuticals, Inc. authorizes a Buyback Plan. - MarketScreener
Catalyst Pharmaceuticals, Inc. announces an Equity Buyback for $200 million worth of its shares. - MarketScreener
Catalyst Pharma Announce New Share Repurchase Program Of $200 Mln - Nasdaq
Catalyst Pharmaceuticals Approves $200 Million Share Repurchase Program - MarketScreener
Catalyst Pharmaceuticals authorizes $200 million share buyback program By Investing.com - Investing.com Canada
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Catalyst Pharmaceuticals Inc-Aktie (CPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Elsbernd Brian | Chief Compliance/Legal Officer |
Sep 08 '25 |
Sale |
20.30 |
30,000 |
609,000 |
271,039 |
5.02%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):